NY-700 is a GPC3-targeted Astatine-211 alpha therapy aiming to address needs of advanced metastatic, pre-transplant, & post-resection HCC patients and is expected to initiate clinical development in 2026. Astatine-211 has shown significant safety & supply advantages over actinium-225 and potential for use in outpatient settings. 

 

NY-303 is a GPC3/NKp46/CD16-targeting bifunctional antibody positioned as a potential best-in-class second-line therapy for HCC. It is differentiated by a unique mechanism of action designed to unlock the biology of non-responders to PD(L)1 Inhibitors (+/- VEGF Inhibitors), 70-85% of HCC patients, and is cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025.​​

​

NY-338 is a CD38/NKp46/CD16-targeting bifunctional antibody positioned as a potential best-in-class second-line therapy for Multiple Myeloma. It is differentiated by a unique mechanism of action addressing the limitations of both daratumumab & BCMA T-cell engagers and is set to enroll patients in its Phase I/II clinical trials in H1 2026. ​​